Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Shogo Marui

Masaki Ogino

Tsuneo Oda

Shoji Kishimoto

Takeshi Fujita

Masatoshi Hazama

Yuji Ishichi

Kohei Notoya

Yasushi Hattori

Hideo Suzuki

Tatsuki Koike

Masaki Seto

Hiroyuki Tawada

Yasutaka Hoashi

Masato Yoshida

Norihito Tokunaga

Yuichi Kajita

Tetsuya Aono

Yuhei Miyanohana

Takahiro Matsumoto

Yoshihide Tomata

Tohru Miyazaki

Koichiro Fukuda

Tatsuhiko Fujimoto

Yoshihiro Banno

Zen-ichi Terashita

Fumio Itoh

Tomokazu Kusumoto

Masafumi Nakao

Kentaro Rikimaru

Hiromichi Sugimoto

Hyun Bin Kang

Takatoshi Yogo

Masuo Yamaoka

Etsuya Matsutani

Hiroyuki Nagamiya

Hye Sun Jeon

Masahira Nakamura

Koki Kato

Cheolhwan Yoon

Chul Yun Rhim

Kwang Ok Kim

Gil Nam Lee

Osamu Yabe

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

The present invention relates to an alkaline earth metal salt or an organic amine salt of a compound represented by the formula [I]: wherein Rand Rare each a hydrogen atom, a halogen atom, or an optionally substituted linear hydrocarbon group; ring A is an optionally further substituted benzene ring; B is an optionally substituted benzene ring; R is a carboxyl group or a linear hydrocarbon group substituted with a carboxyl group and the like. 

Coumarin derivative and use thereof

The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula:in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is &#x2014;NR&#x2014; (in which Ris a hydrocarbon or the like); D is a Calkylene group or the like; E is &#x2014;NH&#x2014; or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and Rmay be taken together with a constituent atom of the ring B to form a ring.

Lipid-rich plaque inhibitors

Cell differentiation inducing amide derivatives, their production and use

Naphtholactams and lactones as bone morphogenetic protein active agents

Heterocyclic compounds, their production and use

There is disclosed a pharmaceutical composition for inhibiting glutaminase which comprises a imidazole derivative or a salt thereof. This compound selectively inhibits the proliferation of tumor cells, and the composition is useful as an anti-cancer agent. There is also disclosed a imidazole derivative having glutaminase inhibitory activity.

Glutaminase inhibitory compounds, compositions, and methods of use

The present invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is 2-methyl-1-propenyl group or isobutyl group; R.sup.2 and R.sup.3 are each hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted acyl group or R.sup.2 and R.sup.3 may form a ring together with the adjacent nitrogen atom; and the bonding mark .about. represents an .alpha.-linkage or .beta.-linkage, or a salt thereof. The compound (I) of the present invention has, among others, angiogenesis inhibiting activity, cell-growth inhibiting activity and immune reaction inhibiting activity, thus being useful as medicines, etc.

6-amino-6-desoxyfumagillols, production and use thereof

The present invention relates to a compound of the formula: ##STR1## wherein A is halogen, N(O)mR.sup.1 R.sup.2, N.sup..sym. R.sup.1 R.sup.2 R.sup.3 .multidot.X.sup..crclbar., S(O)nR.sup.1 or S.sup..sym. (O)mR.sup.1 R.sup.2 .multidot.X.sup..crclbar. where R.sup.1, R.sup.2 and R.sup.3 are each optionally substituted hydrocarbon or heterocyclic group, X.sup..crclbar. is a counter anion; m is an integer of 0 or 1; n is an integer of 0 to 2; R.sup.1 and R.sup.2 may form a nitrogen-containing or a sulfur-containing heterocyclic ring, which may further form a condensed ring, with the adjacent nitrogen atom or sulfur atom, and these nitrogen-containing or sulfur-containing heterocyclic rings may have substituents, Z is O or NR.sup.4 where R.sup.4 is hydrogen or an optionally substituted lower alkyl or aryl group, D is 2-methyl-1-propenyl group or isobutyl group, and E is hydrogen, an optionally substituted hydrocarbon or an optionally substituted acyl group; provided that, when A is chlorine, E is an optionally substituted hydrocarbon or acyl excepting dinitrobenzoyl, a salt thereof, production and use thereof. The novel cyclohexanol derivatives of the present invention have angiogenesis inhibiting activity and anti-tumor activity, and they are used as antirheumatic agents, therapeutic agents of psoriasis, therapeutic agents of diabetic retinopathy and anti-tumor agents.

Cyclohexanol derivatives, production and use thereof

Growing community of inventors

Kobe, Japan

Shogo Marui